Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

•This is a comprehensive summary from the third annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Minimal Residual Disease (MRD) and Immune Profiling (IP) workshop.•MRD is not yet established as a surrogate endpoint but is a prognostic biomarker.•Incorporation of IP as an...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2020-01, Vol.26 (1), p.e7-e15
Main Authors: Holstein, Sarah A., Al-Kadhimi, Zaid, Costa, Luciano J., Hahn, Theresa, Hari, Parameswaran, Hillengass, Jens, Jacob, Allison, Munshi, Nikhil C., Oliva, Stefania, Pasquini, Marcelo C., Shi, Qian, Stadtmauer, Edward A., Waldvogel, Stephanie L., McCarthy, Philip L.
Format: Article
Language:English
Subjects:
CAR T cell
Clinical Trials as Topic
Congresses as Topic
Education
Endpoint
Hematology
Humans
Immune profiling
Minimal residual disease
Multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - therapy
Neoplasm, Residual
Societies, Medical
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•This is a comprehensive summary from the third annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Minimal Residual Disease (MRD) and Immune Profiling (IP) workshop.•MRD is not yet established as a surrogate endpoint but is a prognostic biomarker.•Incorporation of IP as an exploratory endpoint in trial design is recommended. The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2019.09.015